2018
DOI: 10.1016/j.bbrc.2018.02.147
|View full text |Cite
|
Sign up to set email alerts
|

A selective c-Fos/AP-1 inhibitor prevents cartilage destruction and subsequent osteophyte formation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
32
1

Year Published

2018
2018
2024
2024

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 42 publications
(33 citation statements)
references
References 30 publications
0
32
1
Order By: Relevance
“…For instance, mice with a knockout gene that encodes a protease specific to the knee joint might be less likely to develop OA than wild type mice. Genetically modifying mice to find protective factors is a promising avenue in developing future treatments for OA [22]. For example, Motomura et al found that c-Fos/activator protein (AP)-1 inhibitor, T-5224, which inhibits matrix metalloproteinases (MMPs) prevents cartilage destruction and reduces rates of OA in mice [22].…”
Section: Genetically Modified Modelsmentioning
confidence: 99%
See 2 more Smart Citations
“…For instance, mice with a knockout gene that encodes a protease specific to the knee joint might be less likely to develop OA than wild type mice. Genetically modifying mice to find protective factors is a promising avenue in developing future treatments for OA [22]. For example, Motomura et al found that c-Fos/activator protein (AP)-1 inhibitor, T-5224, which inhibits matrix metalloproteinases (MMPs) prevents cartilage destruction and reduces rates of OA in mice [22].…”
Section: Genetically Modified Modelsmentioning
confidence: 99%
“…Genetically modifying mice to find protective factors is a promising avenue in developing future treatments for OA [22]. For example, Motomura et al found that c-Fos/activator protein (AP)-1 inhibitor, T-5224, which inhibits matrix metalloproteinases (MMPs) prevents cartilage destruction and reduces rates of OA in mice [22]. The advantage of using mice which are likely to develop OA is that it saves researchers time and money compared to using wild type mice which have a lower incidence of OA [5,6,8].…”
Section: Genetically Modified Modelsmentioning
confidence: 99%
See 1 more Smart Citation
“…Indeed, MMP-3 has been identi ed in OA synovium and synovia, and its expression levels are regarded to be relative to OA severity and SDF-1 release [12,19,24]. Following the release of MMPs, collagens, and matrix proteins such as ACAN degrade, the OA pathological process accelerates [25]. Our previous studies have determined that levels of col II and ACAN are notably reduced in a spontaneous OA guinea pig model, and they reversibly increased as a consequence of T140 treatment [19].…”
Section: Discussionmentioning
confidence: 99%
“…Early-response genes (both up-and downregulated) exhibited changes in expression as early as 3 hours but generally peaked at 6 hours of FN-f treatment. These early-response genes include many upregulated genes that have been previously implicated in OA, including AP-1 components FOS and JUN 24,37 , NOD2 38 , RIPK2 38 , the aggrecanase ADAMTS4 24,39 , CXCL1, CXCL2, and CXCL3 16 , LIF, TNF [40][41][42] , TNFAIP6 and TNFRSF11B 19 , PTGES 19 , IL6 and IL8 39,41,43,44 . Among genes that decreased early was the transcription factor SP7, which is downregulated by TNF 45 .…”
Section: Fn-f Triggers Both Early-and Late-response Genesmentioning
confidence: 99%